drugset / Trial / NCT00230126
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
Phase 2
Completed
57 enrolled
Ohio State University Comprehensive Cancer Center
Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
Timeline
- Start
- 2005-10
- Primary completion
- 2011-09
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Erlotinib | Small molecule | 175 mg | Oral |
| Subject | Erlotinib | Small molecule | 200 mg | Oral |